| Literature DB >> 30038961 |
Abstract
Aim Current literature emphasizes the effectiveness of computed tomography (CT) and water-soluble contrast agent, Gastrografin, in the investigation of adhesive small bowel obstruction (ASBO). As there is no management protocol for ASBO at our institution, the aim of this study was to determine the effect of imaging methods-CT, Gastrografin challenge (GC), or plain-film X-ray-on patient outcomes in a clinical setting. Methods All 163 emergency presentations of ASBO during the study period between December 2010 and September 2012 were collected retrospectively. Cases were divided into three groups: CT with oral contrast, GC, or plain-film X-ray only. The primary outcome was time to theater. Results Patients investigated with X-ray only were significantly less likely to require surgery (6% in plain-film X-ray vs. 35% and 20% in CT and GC, respectively; p = 0.003). In cases requiring surgery, GC was associated with a 24-hour longer time to imaging than CT ( p < 0.001). The time to theater was 71:25 hours for GC versus 46:39 for CT ( p = 0.039). There was no significant difference in bowel resection or complication rates. Conclusion Patients undergoing water-soluble contrast studies were subjected to unnecessary delays in their clinical course. These delays are costly and avoidable. The development and implementation of an evidence-based protocol for the management of small bowel obstruction is strongly recommended. The lack of a protocol likely caused significant delays in Gastrografin administration, reducing its known benefits for clinical decision-making and length of stay.Entities:
Keywords: Gastrografin; adhesions; computed tomography; management protocol; small bowel obstruction; water-soluble contrast agents
Year: 2018 PMID: 30038961 PMCID: PMC6054586 DOI: 10.1055/s-0038-1666781
Source DB: PubMed Journal: Surg J (N Y) ISSN: 2378-5128
Cohort demographics and management path
|
Total cohort (
| |
|---|---|
| Median age in years (range) | 74 (26–97) |
| Female gender | 95 (58%) |
| After-hours admission | 66 (40%) |
| High-dose group | 45 (28%) |
| Low-dose group | 85 (52%) |
| Plain-film X-ray | 33 (20%) |
| Required surgery | 41 (25%) |
Patient factors associated with surgery
|
No surgery (
|
Surgery (
|
| |
|---|---|---|---|
| Female gender | 68 (56%) | 27 (66%) | 0.34 |
| After-hours admission | 46 (38%) | 19 (46%) | 0.45 |
| Previous history of SBO | 61 (50%) | 10 (24%) | 0.007 |
| Previous abdominal or pelvic surgery | 121 (99%) | 40 (98%) |
0.44
|
| Diabetes mellitus | 18 (15%) | 7 (17%) | 0.80 |
| Cardiovascular comorbidities | 71 (58%) | 30 (73%) | 0.13 |
| Previous abdominal irradiation | 20 (16%) | 2 (5%) | 0.11 |
| Previous abdominal/pelvic malignancy | 54 (44%) | 11 (27%) | 0.07 |
| Anticoagulation | 8 (7%) | 6 (15%) |
0.12
|
Abbreviation: SBO, small bowel obstruction.
Fisher's exact test.
Patient demographics and management by imaging modality
|
CT with oral contrast (
|
Gastrografin challenge (
|
Neither (
|
| |
|---|---|---|---|---|
| Median age in years (range) | 76 (26–97) | 67 (28–90) | 64 (27–91) | 0.08 |
| Female gender | 46 (54%) | 27 (60%) | 22 (67%) | 0.45 |
| After-hours admission | 31 (36%) | 16 (36%) | 19 (58%) | 0.08 |
| Previous abdominal or pelvic operation | 83 (97%) | 45 (100%) | 33 (100%) | 0.40 |
| History of previous SBO | 26 (31%) | 19 (42%) | 26 (78%) | < 0.001 |
| Cardiovascular comorbidities | 60 (71%) | 27 (60%) | 14 (42%) | 0.017 |
| Diabetes mellitus | 18 (21%) | 6 (13%) | 1 (3%) | 0.045 |
| Previous abdominal irradiation | 10 (12%) | 5 (11%) | 7 (21%) | 0.35 |
| Previous abdominal/pelvic malignancy | 30 (35%) | 21 (47%) | 14 (42%) | 0.43 |
| Anticoagulation | 5 (6%) | 6 (13%) | 3 (9%) | 0.35 |
| Surgery required | 30 (35%) | 9 (20%) | 2 (6%) | 0.003 |
| Median length of stay in days (range) | 5 (1–68) | 4 (1–42) | 2 (1–19) | < 0.001 |
Abbreviations: CT, computed tomography; SBO, small bowel obstruction.
Pearson's chi-square test used for categorical variables and the Kruskal–Wallis test used for continuous variables.
Demographics and outcomes of patients who underwent surgery
|
CT with oral contrast (
|
Gastrografin challenge (
|
| |
|---|---|---|---|
| Median age in years (range) | 79 (43–90) | 79 (38–86) | 0.53 |
| Female gender | 18 (60%) | 7 (78%) | 0.56 |
| Operation during day-time | 20 (67%) | 9 (100%) |
0.08
|
| Median length of stay in days (range) | 10 (2–68) | 14 (7–42) | 0.26 |
| Median time to imaging in hours:minutes | 7:55 | 32:24 | <0.001 |
| Median days from imaging to discharge (range) | 10 (2–68) | 13 (6–41) | 0.61 |
| Median time to theater in hours:minutes | 46:39 | 71:25 | 0.039 |
| Surgery > 48 h after admission | 14 (47%) | 8 (89%) |
0.052
|
| Median postoperative days (range) | 8 (1–65) | 9 (4–39) | 0.59 |
| Bowel resection | 11 (37%) | 4 (44%) |
0.71
|
| Number of patients with complications | 13 (43%) | 7 (78%) |
0.13
|
| Readmission within 30 d | 0 | 1 (11%) |
0.23
|
| Readmission within 12 mo | 5 (17%) | 1 (11%) |
1.00
|
Abbreviation: CT, computed tomography.
Fisher's exact test.
Demographics and outcomes of patients who underwent conservative management
|
CT with oral contrast (
|
Gastrografin challenge (
|
Neither (
|
| |
|---|---|---|---|---|
| Median age in years (range) | 74 (26–97) | 67 (28–90) | 64 (27–91) | 0.27 |
| Female gender | 28 (51%) | 20 (56%) | 20 (65%) | 0.83 |
| Median time to imaging in hours:minutes | 5:27 | 25:50 | n/a | <0.001 |
| Median days from imaging to discharge (range) | 3 (0–19) | 3 (1–126) | n/a | 0.86 |
| Median length of stay in days (range) | 3 (1–20) | 4 (1–10) | 2 (1–6) | <0.001 |
| Readmission within 30 d | 7 (13%) | 5 (14%) | 5 (16%) | 0.91 |
| Readmission within 12 mo | 8 (15%) | 10 (28%) | 6 (19%) | 0.20 |
Abbreviation: CT, computed tomography.
Complications of patients who underwent surgery
|
CT with oral contrast (
|
Gastrografin challenge (
|
| |
|---|---|---|---|
| Number of patients with complications b | 13 | 7 | 0.13 |
| Bowel resection | 11 | 4 | 0.71 |
| Wound infection | 1 | 0 | 1.00 |
| Wound dehiscence | 2 | 0 | 0.49 |
| Fistula | 0 | 0 | 0 |
| Fluid collection | 1 | 0 | 1.00 |
| Respiratory | 6 | 1 | 0.13 |
| Urinary | 2 | 1 | 1.00 |
| Line complications | 1 | 0 | 1.00 |
| Other infectious | 4 | 1 | 1.00 |
| Pseudocolitis | 0 | 0 | 0 |
| Cardiac | 5 | 2 | 0.62 |
| Electrolyte and metabolic complication | 3 | 2 | 1.00 |
Fisher's Exact Test.